CANSINOBIO Receives NMPA Acceptance and Priority Review for Five-Component DTaP Booster Vaccine

Bulletin Express

Aug 16

Hong Kong, 16 August 2026—CanSino Biologics Inc. (CANSINOBIO) announced that China’s National Medical Products Administration (NMPA) has formally accepted the company’s new drug application for its five-component tetanus, reduced diphtheria and acellular pertussis combined booster vaccine (Td5cp) for individuals aged six years and older. The Center for Drug Evaluation has also granted the candidate priority review status.\n\nThe Td5cp Adolescent and Adult vaccine targets a market gap: China currently has no approved booster covering diphtheria, tetanus and pertussis for adolescents and adults, although such products are included in routine immunization schedules in major developed markets. Successful commercialization would introduce the first domestic option in this category.\n\nCompared with CANSINOBIO’s three-component infant vaccine (DT3cP Infant) approved in April 2026, the new Td5cp formulation contains two additional pertussis antigen components. Each antigen is individually purified and combined in a controlled ratio, enhancing batch consistency and product stability.\n\nThe company advised shareholders and potential investors to exercise caution when trading its shares following the announcement.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1186363977"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1186363977\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1186363977?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-16 18:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1186363977","market":"us","top_or_hot":-1,"title":"CANSINOBIO Receives NMPA Acceptance and Priority Review for Five-Component DTaP Booster Vaccine","media":"Bulletin Express","content":"<p>Hong Kong, 16 August 2026—CanSino Biologics Inc. (CANSINOBIO) announced that China’s National Medical Products Administration (NMPA) has formally accepted the company’s new drug application for its five-component tetanus, reduced diphtheria and acellular pertussis combined booster vaccine (Td5cp) for individuals aged six years and older. The Center for Drug Evaluation has also granted the candidate priority review status.\\n\\nThe Td5cp Adolescent and Adult vaccine targets a market gap: China currently has no approved booster covering diphtheria, tetanus and pertussis for adolescents and adults, although such products are included in routine immunization schedules in major developed markets. Successful commercialization would introduce the first domestic option in this category.\\n\\nCompared with CANSINOBIO’s three-component infant vaccine (DT3cP Infant) approved in April 2026, the new Td5cp formulation contains two additional pertussis antigen components. Each antigen is individually purified and combined in a controlled ratio, enhancing batch consistency and product stability.\\n\\nThe company advised shareholders and potential investors to exercise caution when trading its shares following the announcement.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CANSINOBIO Receives NMPA Acceptance and Priority Review for Five-Component DTaP Booster Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCANSINOBIO Receives NMPA Acceptance and Priority Review for Five-Component DTaP Booster Vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-16 18:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hong Kong, 16 August 2026—CanSino Biologics Inc. (CANSINOBIO) announced that China’s National Medical Products Administration (NMPA) has formally accepted the company’s new drug application for its five-component tetanus, reduced diphtheria and acellular pertussis combined booster vaccine (Td5cp) for individuals aged six years and older. The Center for Drug Evaluation has also granted the candidate priority review status.\\n\\nThe Td5cp Adolescent and Adult vaccine targets a market gap: China currently has no approved booster covering diphtheria, tetanus and pertussis for adolescents and adults, although such products are included in routine immunization schedules in major developed markets. Successful commercialization would introduce the first domestic option in this category.\\n\\nCompared with CANSINOBIO’s three-component infant vaccine (DT3cP Infant) approved in April 2026, the new Td5cp formulation contains two additional pertussis antigen components. Each antigen is individually purified and combined in a controlled ratio, enhancing batch consistency and product stability.\\n\\nThe company advised shareholders and potential investors to exercise caution when trading its shares following the announcement.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06185","symbol_name":"康希诺生物","start_time":0,"source_url":"","article_id":"1186363977","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1186363977","pubTimestamp":1786874817,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hong Kong, 16 August 2026—CanSino Biologics Inc. (CANSINOBIO) announced that China’s National Medical Products Administration (NMPA) has formally accepted the company’s new drug application for its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06185":"康希诺生物"},"translate_title":"康希诺生物五组分DTaP加强疫苗获NMPA受理及优先审评","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06185":1},"content_text":"Hong Kong, 16 August 2026—CanSino Biologics Inc. (CANSINOBIO) announced that China’s National Medical Products Administration (NMPA) has formally accepted the company’s new drug application for its five-component tetanus, reduced diphtheria and acellular pertussis combined booster vaccine (Td5cp) for individuals aged six years and older. The Center for Drug Evaluation has also granted the candidate priority review status.\\n\\nThe Td5cp Adolescent and Adult vaccine targets a market gap: China currently has no approved booster covering diphtheria, tetanus and pertussis for adolescents and adults, although such products are included in routine immunization schedules in major developed markets. Successful commercialization would introduce the first domestic option in this category.\\n\\nCompared with CANSINOBIO’s three-component infant vaccine (DT3cP Infant) approved in April 2026, the new Td5cp formulation contains two additional pertussis antigen components. Each antigen is individually purified and combined in a controlled ratio, enhancing batch consistency and product stability.\\n\\nThe company advised shareholders and potential investors to exercise caution when trading its shares following the announcement.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}